Florbetapir-(18F) can be used as a reference standard, with possible traceability to pharmacopeial standards such as USP or EP, based on feasibility. AquigenBio products are strictly for analytical purposes and is not intended for human use.

Key Applications:

1. Alzheimer’s Disease Diagnosis

• Florbetapir-(¹⁸F) PET imaging enables in vivo visualization of β-amyloid plaque deposition, a hallmark of Alzheimer’s disease.

• Assists in the early and differential diagnosis of Alzheimer’s from other neurodegenerative conditions.

2. Clinical Decision Support

• Helps physicians determine whether Alzheimer’s disease pathology is present in patients with uncertain diagnoses.

• Supports decisions regarding treatment plans, medication use (e.g., anti-amyloid therapies), and clinical trial enrollment.

3. Patient Selection for Clinical Trials

• Used to screen and stratify patients for inclusion in clinical trials evaluating anti-amyloid therapies or disease-modifying treatments for AD.

4. Monitoring Therapeutic Efficacy (Research Use)

• In research settings, Florbetapir-(¹⁸F) may be used to track changes in amyloid burden over time, especially in patients receiving anti-amyloid immunotherapy.

5. Neuroimaging Research

• Widely used in academic and pharmaceutical research to study the pathophysiology of Alzheimer’s disease, as well as in understanding brain aging and cognitive decline.

Other Details:

• Imaging Modality: PET scan

• Radiotracer Half-life: ~110 minutes

• Administration Route: Intravenous (IV)

<p>The post Florbetapir-(18F) first appeared on AquigenBio.</p>

<p>The post N-Nitroso Florbetapir-(18F) first appeared on AquigenBio.</p>